Клеточные технологии в гематологии
Post on 06-Jan-2016
97 Views
Preview:
DESCRIPTION
TRANSCRIPT
-
, .. .. - , .
-
Ex vivo In vivo
-
-
-
- -CD-34+ -
-
G0G2/S-..
-
G2/S..
-
- , , CD34+ ; CD34+ - , ; CD34+ - .
-
1992-2011 . 590 679 : 1 .-18 ( 10 )
-
1 - HLA- 2 - 3 - 4 -
-
=0,005561,6%7,855,2%7,543,3%9,17,14%6,2
-
20 Event-Free Survival
-
=0,35562,1%9,635,6%10,6
-
=0,1980,3%4,692,9%6,8
-
84,0%10n=13
-
=0,6473,3%13,238,7%15,138,4%13,5()
-
: /1997 2010
146 160 7,9 (0,5-18,7): 98:48
-
2% 97% - 17 (7-40) (100 ) 5% ( )18 (18%)TRM () 48 (33%)
-
1-4 63% 2-4 42% 3-4 15% - 39% 24%
-
: : - : CD34+ CD3+/CD19+ 98% ~ 20% - 4.2 log B- 3.5 log2006 12007 22008 - 152009 22010 2011 2012 9
20-70%90%100% 2-4 1 1 +++++++ +++++ +-++++++++
-
(2008-2010 .) ex vivo 09 2007 . -2007/176, . : 26 2-4 2-4 . 16 1-3 2-4 .
. 2-3 . ( +26 +302 )
-
.
.
ex vivo .
.
-
NK- (18 ). .
- , CD56+ 10-50106 . ( ), (). 14-20 . - 200- CD56+ NK- 5-10 . , . NK- - , , . : CD3-, CD16+,CD56+,CD94+.NK- , MHC I, .
-
: . in vitro . . .
-
ex vivo - - () -2 (-2) . , - . (), , -, .- - : (,,, ) (, .) (- )
-
1993 - New York, Milan, Dsseldorf
2003 - Bone Marrow Donor Worldwide (33 21 ) 2003 .
2005 . 6656 , 42 ( 12 ), 1550
-
,
( CFU-GM CFU-GEMM) -, .
-
14 ( , MethoCult 4338, StemCellTehnologies, Canada) -mix, -, -, -, -. - n = 226 CD34+ n = 612CD34+ (%) 0,827CD34+ (10/) - 103 (n=1004)
-
25 ml RBC HES 20 WBC 0.8 % HES, 1 % Dextran 40, 10 % DMSO 25
-
*
7-8 ()12-15 , ; - - 18-54, , , 34+ 64-84 , 84-154 - , ,
-
* 50%
0,5 - 1% ,
- -
-
-
* - 6 , 100% 36 1-6 / (.., 5 30103 ) , , , , 20 , 20-1500 . , 50% 4 10 40% ,
-
*
1997 . Y , 1998 . RhD+ RhD 2000-2005 . : - (HbE .) .
-
52 (Grenn I. et al, Hodgkins disease: a maernal-to fetal lymphocyte chimera? Lancet, 1960) . -, 90% - 1:106 6 (Lambert NC et al. Arthritis Rheum, 2004, 50, 906-914) 47 / : , -, -, (, .) , , , , , , , ,
-
/ / ,
-
(5% ) ( ), / (, ..)
-
, ,
, / . ,
-
/ in utero
in utero , , ( )
.
, , ,
-
. , . , , , .
-. , 45, -,
Treg ( )
-
, ,
- Treg /
-
, /
(NCA)
JgG I
-
, / ()
, / GM-1 12 (, )
-
* ?
2-4 (11-26%) (48-56%) (Gadi and Nelson, 2007; Gadi et al., 2008). - 62% 12% (Tokita et al., Gadi et al).
-
/
- (Berencsi, 2012)
- : (second hit) (Berencsi, Barcsay, 2012)
-
*
/
: 1/3 , (- -, -, )
Lab investigation, 2006
-
Stem Cells 2005 in press
-
: : -- - - : /
-
.
ex vivo.
.
, . .
.
- .
-
***
top related